Evidence map›Paper›PMID 40628495›Full record

ArticleEuropean journal of hospital pharmacy : science and practice2026

How to manage the overwhelming amount of database-detected interactions? A focus group meeting study on the management of database-detected risks of drug interactions.

Dénes Kleiner, Faraz Haghverdi, Orsolya Szépe, István László Horváth, Szilvia Sebők, Dezső Csupor, András Horváth, Artúr György Balogh, Katalin Monostory, László Kóbori and 6 more

Abstract read
In one paragraph

Article in European journal of hospital pharmacy : science and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Dénes KleinerUniversity Pharmacy Department of Pharmacy Administration, Semmelweis University, Budapest, Hungary kleiner.denes@semmelweis.hu.ORCID 0000-0002-4715-8695
Faraz HaghverdiUniversity Pharmacy Department of Pharmacy Administration, Semmelweis University, Budapest, Hungary.
Orsolya SzépeUniversity Pharmacy Department of Pharmacy Administration, Semmelweis University, Budapest, Hungary.
István László HorváthUniversity Pharmacy Department of Pharmacy Administration, Semmelweis University, Budapest, Hungary.
Szilvia SebőkUniversity Pharmacy Department of Pharmacy Administration, Semmelweis University, Budapest, Hungary.
Dezső CsuporCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
András HorváthNeurocognitive Research Center, Nyírő Gyula National Institute of Psychiatry and Addictology, Budapest, Hungary.
Artúr György BaloghBajcsy-Zsilinszky Hospital and Clinic, Budapest, Hungary.
Katalin MonostoryInstitute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.
László KóboriDepartment of Surgery, Transplantation and Gastroenterology, Semmelweis University, Budapest, Hungary.
Máté BalázsDepartment of Internal Medicine and Oncology (Division of Oncology), Semmelweis University, Budapest, Hungary.
Magdolna DankDepartment of Internal Medicine and Oncology (Division of Oncology), Semmelweis University, Budapest, Hungary.
Csaba Mihály MóczárDepartment of Family Medicine, Semmelweis University, Budapest, Hungary.
Ádám BeczeDepartment of Family Medicine, Semmelweis University, Budapest, Hungary.
András SüleDepartment of Pharmacy, Peterfy Hospital and Clinic, Budapest, Hungary.
Romána ZelkóUniversity Pharmacy Department of Pharmacy Administration, Semmelweis University, Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesDatabase-assisted screening may help detect the risks of drug interactions, but less than 10% of flagged interactions have clinical manifestations, potentially leading to alert fatigue among healthcare providers. To address this issue, this study aimed to develop a concise framework to support the management of database-indicated interaction risks.

methodsA grounded theory approach was used to design, evaluate and develop the framework. Participants included healthcare professionals and laypersons with experience using narrow therapeutic index medications, as well as individuals recommended by them. Two focus group discussions were conducted (N

resultsParticipants identified key decision-making questions for the framework, including the evidence base for interacting drugs, severity and documentation level of the interaction, availability of safer alternatives, and the presence of confounding factors. The framework was considered useful and, following refinement, potentially suitable for clinical implementation. A key insight was that integration into healthcare curricula is essential for achieving long-term impact. Overall, the proposed tool may assist in managing interaction risks in diverse clinical scenarios and reduce alert fatigue among healthcare professionals.

conclusionAlthough further clinical validation is needed, the framework provides a foundation for improving the management of database-detected drug interactions.

Indexed as

Databases, FactualDrug-Related Side Effects and Adverse ReactionsFocus GroupsDrug InteractionsHealth PersonnelHumansCLINICAL MEDICINECOMPLEMENTARY THERAPIESDRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONSEDUCATION, PHARMACYEVIDENCE-BASED MEDICINE

Identifiers

PMID40628495
PMCPMC13151481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.